HealthCare
Clarity is our platform for Severe Asthma and Immunology Diseases.
We are entering Deployment phase in 2025 with our partner clinics
CLARITY platform addresses the Problem of Diagnosing Severe Asthma in a clinical settings. With an integrated solution to detect Immunology Diseases (starting with APDS, HAE and at a later stage Indolent Systemic Masto cytosis):
•Early Detection with AI: uses generative AI models, LLMs, and GCNs to analyze Electronic Health Records (EHR) and patient data, identifying early symptoms and phenotypes associated with severe asthma, APDS, HAE, and similar rare immunology disorders. This allows for earlier and more accurate diagnosis.
•Differential Diagnosis: By leveraging comparative analysis, Clarity differentiates between common and rare immunology disorders. It ranks potential diagnoses, enabling more targeted investigations for conditions like APDS and HAE, which are often overlooked.
•Personalized Screening: Clarity’s AI sub-agents screen patients for specific markers and phenotypes, offering personalized diagnostics and helping clinicians distinguish between severe asthma and overlapping immunology disorders, enhancing the precision of biologic treatments.
•Data Integration: Clarity pulls data from multiple sources (FHIR HL7, EPIC, ECW) to provide a comprehensive view of patient health. This integration helps in recognizing trends and associations in symptoms that are often missed in traditional diagnostic processes.
By addressing these gaps with sophisticated AI and multi-tasking diagnostic agents, Clarity aims to significantly improve early diagnosis, reduce delays, and enhance personalized treatment plans.
